logo
Headwall Group and Laitram Machinery Announce Deployment of Hyperspectral Technology in Food Processing

Headwall Group and Laitram Machinery Announce Deployment of Hyperspectral Technology in Food Processing

Yahoo29-04-2025

Pivotal step in deploying hyperspectral technology across food processing industries at an industrial scale
Laitram Machinery Logo
Headwall Photonics Logo
Bolton, Massachusetts & New Orleans, Louisiana, April 29, 2025 (GLOBE NEWSWIRE) -- Headwall Photonics®, a leader in advanced hyperspectral imaging technology based in Bolton, MA, together with Laitram Machinery, a New Orleans, LA-based leader in automation and equipment solutions for the food processing industry, today announced their strategic partnership. This collaboration signifies a pivotal step in deploying hyperspectral technology across food processing industries at an industrial scale.
Combining Headwall's sophisticated hyperspectral imaging systems with Laitram Machinery's innovative processing equipment, the partnership aims to revolutionize food processing. It focuses on enhancing quality control, maximizing yield, and elevating the efficiency of operations across various food markets.
Mark Willingham, CEO of Headwall, highlighted the broad applications and potential of their technology, stating, "Our deployment of hyperspectral imaging technology across food processing industries represents a significant leap in enabling industrial-scale improvements. This technology provides critical insights that go beyond what is visible to the naked eye, facilitating substantial advancements in food safety, quality, and processing efficiency. While our work with shrimp processing illustrates its immediate impact, the applications extend across numerous food markets, including other seafood applications, as well as poultry, fruits, vegetables, nuts, and pet foods. This versatility underscores our commitment to enhancing the value chain for a wide array of food products, helping our partners like Laitram Machinery achieve and surpass their operational goals."
At Laitram, we foster a culture of continuous innovation, making us leaders in multiple industries. Partnering with Headwall allows us to leverage this innovative spirit and deliver even greater value to our customers," said James Lapeyre, CEO of Laitram Machinery. "Working together, we are enhancing our suite of processing solutions with Headwall's advanced hyperspectral imaging technology. This collaboration enables us to offer even more precise and efficient quality control capabilities, further empowering our customers to excel in their operations and meet the high standards of today's food industry."
The integration of Headwall's hyperspectral imaging into Laitram Machinery's processing solutions marks a new era in food processing technology. By detecting and analyzing the chemical and physical properties of food products, this technology allows for unparalleled precision in sorting and quality control. Both companies will be exhibiting at the Seafood Processing Global Expo, 6 to 8 May 2025 in Barcelona: Headwall Group in stand 3NN400 and Laitram Machinery in stand 3HH201.
For more information about the partnership between Headwall and Laitram Machinery, or to learn more about the application of hyperspectral technology in food processing, please visit headwallphotonics.com
About The Headwall Group
The Headwall Group, headquartered in Bolton MA, includes the industry leaders Headwall Photonics, EVK DI Kerschhaggl GmbH, inno-spec GmbH, perClass BV, and Holographix, together driving innovation in hyperspectral imaging and optical component technologies. Comprehensive technology expertise is the foundation of global leadership in Machine Vision and Remote Sensing applications, offering end-to-end solutions that are critical in these fields. The Headwall Group is dedicated to harnessing this expertise to enhance food quality, revolutionize recycling efficiency, and refine industrial processes, all while fostering a more sustainable future. For more information, please visit headwallphotonics.com
About Laitram Machinery
Based in New Orleans, LA, Laitram Machinery is a world leader in developing innovative automation solutions and equipment for the food processing industry. Committed to efficiency, quality, and sustainability, Laitram Machinery aims to enhance the productivity and profitability of food processors around the globe. For more information, please visit laitrammachinery.com
Attachments
Laitram Machinery Logo
Headwall Photonics Logo
CONTACT: Ross Nakatsuji Headwall Photonics, Inc. +1 978-353-4051 rnakatsuji@headwallphotonics.com Karen Quaas Laitram Machinery +1 504-352-8024 Karen.Quaas@laitram.comSign in to access your portfolio

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Getty Images and Stability AI face off in British copyright trial that will test AI industry
Getty Images and Stability AI face off in British copyright trial that will test AI industry

The Hill

time20 minutes ago

  • The Hill

Getty Images and Stability AI face off in British copyright trial that will test AI industry

LONDON (AP) — Getty Images is facing off against artificial intelligence company Stability AI in a London courtroom for the first major copyright trial of the generative AI industry. Opening arguments before a judge at the British High Court are scheduled for Monday. The trial could last for three weeks. Stability, based in London, owns a widely used AI image-making tool that sparked enthusiasm for the instant creation of AI artwork and photorealistic images upon its release in August 2022. OpenAI introduced its surprise hit chatbot ChatGPT three months later. Seattle-based Getty has argued that the development of the AI image maker, called Stable Diffusion, involved 'brazen infringement' of Getty's photography collection 'on a staggering scale.' Tech companies have long argued that 'fair use' or 'fair dealing' legal doctrines in the United States and United Kingdom allow them to train their AI systems on large troves of writings or images. Getty was among the first to challenge those practices when it filed copyright infringement lawsuits in the United States and the United Kingdom in early 2023. 'What Stability did was inappropriate,' Getty CEO Craig Peters told The Associated Press in 2023. He said creators of intellectual property should be asked for permission before their works are fed into AI systems rather than having to participate in an 'opt-out regime.' Stability has argued that the case doesn't belong in the United Kingdom because the training of the AI model technically happened elsewhere, on computers run by U.S. tech giant Amazon. Similar cases in the U.S. have not yet gone to trial. Stable Diffusion's roots trace to Germany, where computer scientists at Ludwig Maximilian University of Munich worked with the New York-based tech company Runway to develop the original algorithms. The university researchers credited Stability AI for providing the servers that trained the models, which require large amounts of computing power.

Getty Images and Stability AI face off in British copyright trial that will test AI industry
Getty Images and Stability AI face off in British copyright trial that will test AI industry

San Francisco Chronicle​

time20 minutes ago

  • San Francisco Chronicle​

Getty Images and Stability AI face off in British copyright trial that will test AI industry

LONDON (AP) — Getty Images is facing off against artificial intelligence company Stability AI in a London courtroom for the first major copyright trial of the generative AI industry. Opening arguments before a judge at the British High Court are scheduled for Monday. The trial could last for three weeks. Stability, based in London, owns a widely used AI image-making tool that sparked enthusiasm for the instant creation of AI artwork and photorealistic images upon its release in August 2022. OpenAI introduced its surprise hit chatbot ChatGPT three months later. Seattle-based Getty has argued that the development of the AI image maker, called Stable Diffusion, involved 'brazen infringement' of Getty's photography collection 'on a staggering scale." Tech companies have long argued that 'fair use' or 'fair dealing' legal doctrines in the United States and United Kingdom allow them to train their AI systems on large troves of writings or images. Getty was among the first to challenge those practices when it filed copyright infringement lawsuits in the United States and the United Kingdom in early 2023. 'What Stability did was inappropriate,' Getty CEO Craig Peters told The Associated Press in 2023. He said creators of intellectual property should be asked for permission before their works are fed into AI systems rather than having to participate in an 'opt-out regime." Stability has argued that the case doesn't belong in the United Kingdom because the training of the AI model technically happened elsewhere, on computers run by U.S. tech giant Amazon. Similar cases in the U.S. have not yet gone to trial. Stable Diffusion's roots trace to Germany, where computer scientists at Ludwig Maximilian University of Munich worked with the New York-based tech company Runway to develop the original algorithms. The university researchers credited Stability AI for providing the servers that trained the models, which require large amounts of computing power.

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders

Business Wire

time29 minutes ago

  • Business Wire

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V. ('Avanzanite'), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe' Share 'This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe,' said Adam Plich, Founder and CEO of Avanzanite. 'We provide biotech partners with a capital-efficient path to sustainable patient access – without the burden of building a costly local infrastructure. We look forward to working with Agios to help bring PYRUKYND® to patients across Europe, further advancing our efforts to set a new benchmark for biotech commercial and distribution partnerships in the region. This is just the beginning.' PYRUKYND®, a first-in-class, oral, pyruvate kinase (PK) activator, is approved by the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the treatment of adult patients with PK deficiency. PK deficiency is an ultra-rare, inherited condition that causes premature red blood cell breakdown, leading to chronic anemia, serious complications, and reduced quality of life. Until recently, there were no approved treatments. Agios also has a robust mid- and late-stage pipeline, with clinical programs focused on other rare diseases, including thalassemia and sickle cell disease. The partnership also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand into 32 European countries, including new territories of Italy, France, the UK, Romania, and Spain. 'Avanzanite goes truly pan-European,' concluded Plich. 'And as we expand across the continent, our promise stays the same – making sure no patient is left behind.' About Avanzanite Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the company partners with biotech innovators to unlock the full commercial value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe's complex landscape like master chess players – ensuring no patient is left behind. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store